A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and quality of life in patients with genital psoriasis over 32 weeks.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/apremilast-shows-sustained-benefit-genital-psoriasis-2025a1001024?src=rss
Author :
Publish date : 2025-12-23 02:36:00
Copyright for syndicated content belongs to the linked Source.
